Exosome scams, five‑day "doctors" and hormone‑laced baby creams expose cracks in China’s consumer safety net

Scandals point to regulatory gaps

A string of recent exposes — from CCTV’s 315 consumer program (央视315晚会) and independent tester Laoba Test (老爸评测) — has laid bare how weak oversight is putting Chinese consumers at risk. It has been reported that one company, identified as Jiebo‑sai’er Biotechnology (婕波噻尔生物科技有限公司), allegedly injected patients with an unlabelled, frozen “exosome” serum and charged as much as RMB 60,000 per treatment. Separately, Laoba Test reportedly screened 105 “disinfection‑class” baby creams and found forbidden steroid additives in 77 samples — a failure rate of about 73%.

Science, platforms and profiteering

Exosomes — bioactive particles secreted during cell culture — remain under clinical study, not a proven panacea. Yet dozens of clinics and vendors have marketed them as cures for aging, epilepsy and diabetes. CCTV named multiple outfits, including Haolin (灏麟（天津）生物科技有限公司), Chengxing Medical Aesthetic Clinic (天津市诚星医疗美容诊所有限公司) and others; it has been reported that many of these products are produced, labelled or sold outside regulatory lines. Even established platforms were implicated: SoYoung (新氧) reportedly listed exosome services that have since been taken down. When a scientific concept is commercialised before clinical validation, is that science communication — or science packaging?

Cheap licences, “three‑no” products and three‑no personnel

The problem is structural. It has been reported that Guangzhou Guangda Hospital (广州广大医院) ran short courses promising "zero‑background, five‑day" training to put trainees into medical‑aesthetic roles — a practice that converts complex medical procedures into weekend skills. At the same time, so‑called "消字号" (disinfection‑class) creams, legally allowed only for antiseptic use, are being marketed as eczema remedies while concealing steroid adulteration. Business‑registry data from Tianyancha (天眼查) show the sector is vast — over 180,000 medical‑aesthetic companies — and a measurable share has legal or regulatory blemishes. How many regulatory landmines must consumers step on before trust is rebuilt?

Enforcement now, structural reform next

Regulators have moved: joint investigation teams involving market supervision, health and police departments have been dispatched; Chengdu ordered shutdowns and Tianjin opened probes. But history suggests the post‑315 clean‑ups are periodic rather than structural. Civil watchdogs such as Laoba Test have repeatedly flagged dangers ahead of official action — a useful complement, but also a sign that regulators are often reactive. Amid rising global scrutiny of biotech, export controls and the reputational stakes for Chinese life‑sciences firms are higher than ever. Fixing this will require more than raids and takedowns; it demands platform accountability, tougher pre‑market verification for novel biological products, and sustained supervision so that compliance becomes the baseline, not an annual scramble.